Announced details
Anti-aging and longevity therapeutics; evaluation of safety and tolerability
A basic agreement has been signed covering the clinical development, joint research and commercialization of RS5614 in Saudi Arabia. A clinical trial agreement has now been signed.
A medical research institution of the Saudi Arabian government
KAIMRC (Saudi Arabia)
The impact on results for the current fiscal year is currently expected to be minor. If any matters requiring disclosure arise, they will be disclosed promptly.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | PAI-1 inhibitor RS5614 |
| Counterparty | King Abdullah International Medical Research Center (KAIMRC) |
| Counterparty overview | A medical research institution of the Saudi Arabian government |
| Relationship with the Company | A basic agreement has been signed covering the clinical development, joint research and commercialization of RS5614 in Saudi Arabia. A clinical trial agreement has now been signed. |
| Contract Date | 21 July 2026 (the date on which the signing of the clinical trial agreement was announced; the agreement execution date itself is Not disclosed) |
| Launch date | It was decided that the trial would commence as of the announcement on 21 July 2026. The specific trial commencement date is Not disclosed |
| Applicable area | Anti-aging and longevity therapeutics; evaluation of safety and tolerability |
| Location | KAIMRC (Saudi Arabia) |
| Impact on Business Performance | The impact on results for the current fiscal year is currently expected to be minor. If any matters requiring disclosure arise, they will be disclosed promptly. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The trial is being commenced as a concrete initiative to advance the clinical evaluation of RS5614 in Saudi Arabia, based on the basic agreement signed on 6 October 2025.